Braeburn Pharmaceuticals

BRIXADI (WEEKLY DOSING)

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Braeburn Pharmaceuticals

Brixadi (Weekly Dosing) HCPCS:

J0577

HCPCS Code Descriptor:

Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy

Category:

J Code

Brixadi (Weekly Dosing) NDCs:

58284-0216-01, 58284-0208-01, 58284-0224-01, 58284-0232-01

Primary Type:

Anti-Addiction

Generic/Specialty Status:

Single-Source

Package Type:

Not Found

Route of Administration:

Subcutaneous

Brixadi (Weekly Dosing) CPT Codes:

-96372 - Therapeutic, prophylactic, and diagnostic injections and infusions (excludes chemotherapy and other highly complex drug or highly complex biologic agent administration)

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Brixadi (Weekly Dosing):

BRIXADI (WEEKLY DOSING) is aligned to the J Code: J0577. BRIXADI (WEEKLY DOSING) is an Anti-Addiction drug produced by Braeburn Pharmaceuticals and administered via the Subcutaneous route of administration.

ACCESS PRICING AND MORE BY REGISTERING

J0577 Added Date:

4/1/24

J0577 Effective Date:

4/1/24

J0577 Deactive Date:

HCPCS Active

Brixadi (Weekly Dosing) billing and coding information can be found through Braeburn Pharmaceuticals at the link below:
Brixadi (Weekly Dosing) patient assistance information can be found through Braeburn Pharmaceuticals at the URL: https://www.brixadi.com/
BRIXADI (WEEKLY DOSING) prescribing information can be found at the link below:
Our team has not yet identified a source of side effect information for BRIXADI (WEEKLY DOSING)